pSivida Corp. (NASDAQ:PSDV) has been given a consensus rating of “Buy” by the six analysts that are covering the stock, AnalystRatings.NET reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $6.25.
In related news, CEO Paul Ashton sold 120,000 shares of the company’s stock in a transaction on Tuesday, December 22nd. The shares were sold at an average price of $5.39, for a total transaction of $646,800.00. Following the completion of the sale, the chief executive officer now directly owns 440,741 shares in the company, valued at approximately $2,375,593.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Leonard S. Ross sold 33,950 shares of the company’s stock in a transaction on Tuesday, December 22nd. The shares were sold at an average price of $5.39, for a total transaction of $182,990.50. The disclosure for this sale can be found here.
Several analysts recently issued reports on the stock. TheStreet lowered shares of pSivida Corp. from a “hold” rating to a “sell” rating in a research report on Friday, November 6th. FBR & Co. started coverage on shares of pSivida Corp. in a research report on Thursday, October 15th. They set an “outperform” rating and a $6.00 price target on the stock. Ladenburg Thalmann reissued a “buy” rating on shares of pSivida Corp. in a research note on Tuesday. Zacks Investment Research downgraded shares of pSivida Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, September 16th. Finally, Northland Securities reissued a “buy” rating on shares of pSivida Corp. in a research note on Thursday, December 17th.
Shares of pSivida Corp. (NASDAQ:PSDV) opened at 4.73 on Thursday. pSivida Corp. has a 12-month low of $3.23 and a 12-month high of $5.81. The firm’s market cap is $139.14 million. The firm’s 50-day moving average is $3.93 and its 200-day moving average is $3.90.
pSivida Corp. (NASDAQ:PSDV) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Analysts predict that pSivida Corp. will post ($0.65) earnings per share for the current fiscal year.
pSivida Corp. is a biotechnology company, which is engaged in the development of sustained-release drug-delivery products for treating eye diseases. The Company offers products for treatment of back-of-the-eye diseases. The Company’s lead development product, Medidur is used for posterior of the eye (NASDAQ:PSDV). Medidur is in Phase III clinical trials. The Company’s pre-clinical development program is focused on developing products using its platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat ophthalmic diseases, such as wet and dry age-related macular degeneration (AMD), glaucoma and osteoarthritis, among others. Its Durasert technology platform delivers therapeutics for predetermined periods of time ranging from days to years. Its Tethadur technology system utilizes BioSilicon, nanostructured elemental silicon, designed to provide sustained delivery of biologic molecules, such as peptides, proteins and antibodies.